1000 Skokie Boulevard
Suite 350
Wilmette, IL 60091
United States
847 388 0349
https://www.monopartx.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 9
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | Co-Founder, CEO, President & Director | 662,19k | N/D | 1984 |
Ms. Kim R. Tsuchimoto CPA | CFO, Secretary, Treasurer & Director | 329,93k | N/D | 1963 |
Mr. Andrew J. Cittadine M.B.A. | Chief Operating Officer | 388,37k | N/D | 1973 |
Dr. Patrice P. Rioux M.D., Ph.D. | Acting Chief Medical Officer | N/D | N/D | 1951 |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
L'ISS Governance QualityScore di Monopar Therapeutics Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.